Skip to Content
Merck
All Photos(1)

Documents

76884

Supelco

Anthranilamide

matrix substance for MALDI-MS, ≥99.0% (HPLC)

Synonym(s):

2-AB, 2-Aminobenzamide, Anthranilic acid amide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
2-(H2N)C6H4CONH2
CAS Number:
88-68-6
Molecular Weight:
136.15
Beilstein:
508509
EC Number:
201-851-2
MDL number:
MFCD00007981
UNSPSC Code:
12000000
PubChem Substance ID:
329767409
NACRES:
NA.21

grade

matrix substance for MALDI-MS

Quality Level

100

Assay

≥99% (NT)
≥99.0% (HPLC)

form

crystals

technique(s)

MALDI-MS: suitable

mp

111-113 °C (lit.)

cation traces

Ba: ≤5 mg/kg
Ca: ≤5 mg/kg
Cd: ≤5 mg/kg
Co: ≤5 mg/kg
Cr: ≤5 mg/kg
Cu: ≤5 mg/kg
Fe: ≤30 mg/kg
K: ≤50 mg/kg
Mg: ≤5 mg/kg
Mn: ≤5 mg/kg
Na: ≤150 mg/kg
Ni: ≤5 mg/kg
Pb: ≤5 mg/kg
Zn: ≤5 mg/kg

SMILES string

NC(=O)c1ccccc1N

InChI

1S/C7H8N2O/c8-6-4-2-1-3-5(6)7(9)10/h1-4H,8H2,(H2,9,10)

InChI key

PXBFMLJZNCDSMP-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Used for non-selective, efficient fluorescent labeling of glycans. Slightly less sensitive than anthranilic acid (2-AA) for glycan labeling.

Analysis Note

metal trace analysis (ICP) corresponds to requirements

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H319

Hazard Classifications

Eye Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

>365.0 °F

Flash Point(C)

> 185 °C

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCD5145
BCBW6851
BCBM7513V
BCBM7513

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yan Cai et al.
The Analyst, 138(21), 6270-6276 (2013-09-07)
Analysis of oligosaccharides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is often limited by their low ionization efficiency and inadequate fragmentation information. Derivatizations of oligosaccharides to enhance their ionization in MS are widely used, but most of these
Nicholas T Ventham et al.
PloS one, 10(4), e0123028-e0123028 (2015-04-02)
Serum N-glycans have been identified as putative biomarkers for numerous diseases. The impact of different serum sample tubes and processing methods on N-glycan analysis has received relatively little attention. This study aimed to determine the effect of different sample tubes
Antonio da Silva et al.
Leukemia & lymphoma, 55(7), 1609-1617 (2013-09-13)
Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here we report the preclinical development of the proposed biosimilar rituximab (GP2013). Post-translational modifications and bioactivities of GP2013 versus originator rituximab were engineered and monitored
Lei Zhu et al.
mAbs, 6(6), 1474-1485 (2014-12-09)
CTLA4-Ig is a highly glycosylated therapeutic fusion protein that contains multiple N- and O-glycosylation sites. Glycosylation plays a vital role in protein solubility, stability, serum half-life, activity, and immunogenicity. For a CTLA4-Ig biosimilar development program, comparative analytical data, especially the
Meritxell Balmaña et al.
Clinica chimica acta; international journal of clinical chemistry, 442, 56-62 (2015-01-18)
Pancreatic adenocarcinoma (PDAC) usually shows an enhanced expression of sialyl-Lewis X (sLe(x)) and related epitopes. PDAC may secrete some of the proteins carrying such increased sLe(x) determinant into serum, so they could be used as PDAC markers. Previously, we identified
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service